Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.

van Eyk HJ, Blauw LL, Bizino MB, Wang Y, van Dijk KW, de Mutsert R, Smit JWA, Lamb HJ, Jazet IM, Rensen PCN

Scientific reports10 Jul 2019Cited by 5 (Europe PMC)

PMID31292457PMCIDPMC6620358DOI10.1038/s41598-019-45593-2PepBankPUB-31292457

Summary

Cholesteryl ester transfer protein (CETP) is mainly expressed by Kupffer cells in the liver. A reduction of hepatic triglyceride content (HTGC) by pioglitazone or caloric restriction is accompanied by a decrease in circulating CETP. Since GLP-1 analogues also reduce HTGC, we assessed whether liraglutide decreases CETP. Furthermore, we investigated the association between HTGC and CETP in a population-based cohort. In a placebo-controlled trial, 50 patients with type 2 diabetes were randomly assigned to treatment with liraglutide or placebo added to standard care. In this trial and in 1,611 participants of the Netherlands Epidemiology of Obesity (NEO) study, we measured HTGC and circulating CETP by proton magnetic resonance spectroscopy and ELISA, respectively. The HTGC was decreased in the liraglutide group (-6.3%; 95%CI of difference [-9.5, -3.0]) but also in the placebo group (-4.0%; 95%CI[-6.0, -2.0]), without between-group differences. CETP was not decreased by liraglutide (-0.05 µg/mL; 95%CI[-0.13, 0.04]) or placebo (-0.04 µg/mL; 95%CI[-0.12, 0.04]). No association was present between HTGC and CETP at baseline (β: 0.002 µg/mL per %TG, 95%CI[-0.005, 0.009]) and between the changes after treatment with liraglutide (β: 0.003 µg/mL per %TG, 95%CI[-0.010, 0.017]) or placebo (β: 0.006 µg/mL per %TG, 95%CI[-0.012,0.024]). Also, in the cohort n o association between HTGC and CETP was present (β: -0.001 µg/mL per SD TG, 95%CI[-0.005, 0.003]). A reduction of HTGC after treatment with liraglutide or placebo does not decrease circulating CETP. Also, no association between HTGC and CETP was present in a large cohort. These findings indicate that circulating CETP is not determined by HTGC.Clinical Trial Registration: Clinicaltrials.gov (NCT01761318).

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, hepatic triglyceride content fell with liraglutide and also with placebo, with no between-group difference.
In plain wordsIn adults with type 2 diabetes, liver fat fell with liraglutide and also with placebo, with no difference between them.
Peptide
Liraglutide
Outcome
No significant changeHepatic triglyceride content (HTGC)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
HTGC change
−6.3%
liraglutide
HTGC change
−4%
placebo
Source sentences
Summary
The HTGC was decreased in the liraglutide group (-6.3%; 95%CI of difference [-9.5, -3.0]) but also in the placebo group (-4.0%; 95%CI[-6.0, -2.0]), without between-group differences.
1 context sentence(design, population, supporting numbers)
Summary · context
In a placebo-controlled trial, 50 patients with type 2 diabetes were randomly assigned to treatment with liraglutide or placebo added to standard care.
Show in the study text Report a problemFND-3129245701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, circulating CETP did not decrease with liraglutide or with placebo.
In plain wordsIn adults with type 2 diabetes, the blood level of the protein CETP did not fall with liraglutide or with placebo.
Peptide
Liraglutide
Outcome
No significant changeCirculating CETP
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
CETP change
−0.05 µg/mL
liraglutide
CETP change
−0.04 µg/mL
placebo
Source sentences
Summary
CETP was not decreased by liraglutide (-0.05 µg/mL; 95%CI[-0.13, 0.04]) or placebo (-0.04 µg/mL; 95%CI[-0.12, 0.04]).
1 context sentence(design, population, supporting numbers)
Summary · context
In a placebo-controlled trial, 50 patients with type 2 diabetes were randomly assigned to treatment with liraglutide or placebo added to standard care.
Show in the study text Report a problemFND-3129245702
03HumanRandomized controlled trialMechanism
In adults with type 2 diabetes treated with liraglutide, changes in hepatic triglyceride content were not associated with changes in circulating CETP.
In plain wordsIn adults with type 2 diabetes treated with liraglutide, changes in liver fat were not linked to changes in blood CETP.
Peptide
Liraglutide
Outcome
No significant changeAssociation between changes in HTGC and CETP after liraglutide
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
and between the changes after treatment with liraglutide (β: 0.003 µg/mL per %TG, 95%CI[-0.010, 0.017])
1 context sentence(design, population, supporting numbers)
Summary · context
In a placebo-controlled trial, 50 patients with type 2 diabetes were randomly assigned to treatment with liraglutide or placebo added to standard care.
Show in the study text Report a problemFND-3129245703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial page ClinicalTrials.govUpdated 5 May 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.